Northeast Ohio GRIDs Monitor

Groups of Regional Industry Drivers (GRIDs) were identified in Northeast Ohio (NEO). GRIDs are wealth-creating industries that have a strong regional specialization, growing output, rising productivity, and local competitive advantage. Overall, the three identified GRIDs—Professional Services, Growing Legacy Manufacturing, and Oil and Gas—contributed nearly 40% ($90.4 billion) to NEO’s total output and employed 20% (369,054 people) of NEO workforce in 2018. This research provides an update on the performance of GRIDs economy focusing on 2017-18 changes and projections for 2019. Calculations in this monitor are based on the data from Moody\u27s Analytics Economy.com

New Way in Cancer Therapy: PD-1 Inhibitors and Hematologic Diseases

Programed death-1 (PD-1) is an immune checkpoint pathway used by cancer cells to evade the anti-cancer activity of T cells. If this pathway is active, inhibitory signals create an unresponsive state, bringing about the tumor growth. Nowadays, the PD-1/PD-L1, L2 inhibitor therapy shows a new way of treatment to clinicians who are working with hemato-oncologic cancers. Some diseases, such as classic Hodgkin lymphoma (cHL) and primary mediastinal large-B-cell lymphoma, that express large amounts of programed death-ligand 1(PD-L1), may be a good target of such a therapy. In hematology, the anti-PD-1 therapy is used successfully and safely in cHL. Other studies are limited, or the results are not available yet. Although most of the diseases, except chronic lymphocytic leukemia and multiple myeloma, show meaningful responses, when using these drugs, we must carefully monitor autoimmune and rare, but serious side effects. In this paper, we emphasize the use of PD-1 inhibitors in hematology

Efficacy comparison of levofloxacin and rifaximin prophylaxis in patients undergoing allogeneic stem cell transplantation

..